BEGIN ARTICLE PREVIEW:
We now know that at least two of the leading coronavirus vaccine candidates appear to be highly effective. But there are several important things that we don’t yet know about the COVID-19 vaccines. In this Motley Fool Live video recorded on Nov. 16, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss some of these key unanswered questions.
Corinne Cardina: We will be looking at the raw data for these interim results that have come out from Moderna (NASDAQ:MRNA) and from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). When that raw data becomes available, Keith, is there anything specific you are going to be looking for to help figure out what happens next?
Keith Speights: Yeah. There really are two things that I will personally be looking for in that raw data. One is how effective the vaccine is in the different age groups. Some vaccines are going to be more effective for younger people versus older people or vice versa. That could be important in terms of just the market opportunity for whatever vaccine it might be.
The other thing I would be looking for is the durability. How long the vaccines …
END ARTICLE PREVIEW